Jim Mom­tazee's Pa­tient Square leads $150M+ ad­di­tion to Kriya Ther­a­peu­tic­s' 'main­stream' gene ther­a­py am­bi­tions

Last year
Financing
Startups

British bil­lion­aire Joe Lewis in­dict­ed for al­leged in­sid­er trad­ing scheme in­volv­ing Mi­rati, Sol­id Bio shares

Last year
People

GSK pulls plans to mar­ket ane­mia drug in EU and oth­er mar­kets, cit­ing 're­duced op­por­tu­ni­ty'

Last year
Pharma

In­fin­i­ty Phar­ma­ceu­ti­cals lays off 78% of staff, shrinks board af­ter MEI merg­er fail

Last year
Deals

Ex­clu­sive: Cell ther­a­py CD­MO Kin­cell launch­es, and the spin­out is val­ued at $66M, with CEO look­ing for carve-outs

Last year
Cell/Gene Tx
Manufacturing

IQVIA and Pro­pel to hold on deal close as FTC case pro­ceeds

Last year
Marketing

Boehringer In­gel­heim, Eli Lil­ly's Jar­diance nabs ap­proval in Eu­rope for chron­ic kid­ney dis­ease

Last year
Pharma
FDA+

Ma­chine learn­ing, AI are chang­ing up how mar­keters think about ‘next best ac­tions’ to reach physi­cians

Last year
Pharma
Marketing

Gilead re­news IT con­tract with Cog­nizant in bid to more quick­ly bring drugs to mar­ket 

Last year
Deals
Pharma

The End­points Slack in­ter­view: Lux's Josh Wolfe on AI hype, biotech mar­kets, Twit­ter and more

Last year
People

Mar­ket­ingRx roundup: Sanofi teas­es #De­feat­Menin­gi­tis on so­cial; Mod­er­na launch­es mR­NA­Mon­day se­ries on Threads

Last year
Pharma
Marketing

An­oth­er win for Novo's semaglu­tide? Physi­cians pre­fer it most in the emerg­ing field of NASH treat­ments, sur­vey finds

Last year
Pharma
Marketing

Three take­aways and three burn­ing ques­tions for Chris Viehbacher's cost-cut­ting fu­ture at Bio­gen

Last year
Pharma

Tar­sus scores first FDA ap­proval for treat­ment of red, itchy eyes caused by mites

Last year
Pharma
FDA+

Cor­rect­ed: Roche is not mov­ing for­ward with SQZ pro­gram, send­ing the biotech in­to strate­gic re­view

Last year
Deals

Lari­mar to kick off high­er dose of lead rare dis­ease drug, ini­ti­ate OLE tri­al

Last year
R&D
FDA+

Bris­tol My­ers in­vests $35M in­to Im­mat­ics; Fi­bro­Gen names new CEO

Last year
News Briefing

Bio­gen ex­pects to re­duce head­count by 1,000 un­der $700M op­er­a­tional sav­ings plan 

Last year
People

Hu­mani­gen warns of bank­rupt­cy af­ter fail­ing to bounce back from Covid-19 EUA re­jec­tion 

Last year
R&D
Pharma

Astel­las en­lists Pep­tiDream in search for pro­tein de­graders as it looks to act fast in hot field

Last year
Deals

Ab­Cellera hopes to restart patent in­fringe­ment law­suits against Berke­ley Lights af­ter US patent of­fice de­nies ...

Last year
Law

Stoke Ther­a­peu­tics un­veils more da­ta on stud­ies of Dravet drug, hint­ing at im­prove­ments to cog­ni­tion and be­hav­ior

Last year
R&D

Ex­elix­is, Te­va reach set­tle­ment on Cabome­tyx patent dis­pute

Last year
Pharma
Law

Te­va and Alvotech strike deal for 'in­creased in­volve­men­t' at Alvotech's trou­bled Ice­land site

Last year
Deals
Pharma
First page Previous page 306307308309310311312 Next page Last page
A service from the Financial Times